0.35
-0.0984(-21.94%)
Currency In USD
| Previous Close | 0.45 |
| Open | 0.44 |
| Day High | 0.44 |
| Day Low | 0.35 |
| 52-Week High | 3 |
| 52-Week Low | 0.35 |
| Volume | 1.81M |
| Average Volume | 872,136 |
| Market Cap | 3.05M |
| PE | -0.4 |
| EPS | -0.87 |
| Moving Average 50 Days | 0.66 |
| Moving Average 200 Days | 0.88 |
| Change | -0.1 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $3.46 as of June 15, 2025 at a share price of $0.35. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $9.03 as of June 15, 2025 at a share price of $0.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial DesignGLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical c
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire Inc.
May 15, 2025 12:30 PM GMT
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and re
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
GlobeNewswire Inc.
May 13, 2025 12:30 PM GMT
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar MarketGlen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Co